Incyte acquires global rights to MorphoSys’ tafasitamab
ImmunotherapyDrug ApprovalLicense out/inADC
Preview
Source: Pharmaceutical Technology
A CD19-targeting immunotherapy, tafasitamab is approved as a combination regimen to treat B-cell lymphoma. Credit: CI Photos / Shutterstock.com.
Incyte has acquired sole worldwide rights to tafasitamab, a humanised Fc-modified CD19-targeting immunotherapy, through an asset purchase agreement with MorphoSys.
The deal grants Incyte complete control of the development and commercialisation of tafasitamab worldwide.
The arrangement supersedes a previous collaboration between the two companies entered in 2020, which involved shared responsibilities for tafasitamab in the US.
See Also:INCB-161734 by Incyte for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
INCB-161734 by Incyte for Non-Small Cell Lung Cancer: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
Tafasitamab is marketed as Monjuvi in the US and as Minjuvi elsewhere in the world. It is currently approved for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
The drug is also undergoing clinical trials for other indications, including first-line DLBCL, relapsed or refractory follicular lymphoma and marginal zone lymphoma.
Originally licensed from Xencor in 2010, tafasitamab incorporates an XmAb-engineered Fc domain, enhancing its ability to induce B-cell lysis through immune effector mechanisms. XmAb is a trademark of Xencor.
In the US, Monjuvi is approved in combination with lenalidomide for specific DLBCL patients not eligible for autologous stem cell transplant.
In Europe, Minjuvi has received conditional marketing authorisation for similar patient groups.
Ongoing combination trials continue to explore tafasitamab’s potential to treat B-cell malignancies, although its efficacy and safety in these investigational indications have yet to be confirmed in trials.
Incyte CEO Hervé Hoppenot stated: “This new agreement with MorphoSys provides Incyte with exclusive global rights to tafasitamab and full control over its development and commercialisation, allowing us to realise significant operating efficiencies and cost synergies.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.